Navigation Links
Allscripts Announces Convertibility of its Outstanding 3.50 Percent Senior Debentures
Date:6/10/2009

CHICAGO, June 10 /PRNewswire-FirstCall/ -- Allscripts announced today that its 3.50 percent Convertible Senior Debentures due 2024 (the "Debentures") are now convertible at the option of the holders of the Debentures and will remain convertible during the fiscal quarter ending August 31, 2009. Any determinations regarding the convertibility of the Debentures during future periods will be made in accordance with the terms of the indenture under which the Debentures were issued (the "Indenture").

The Debentures became convertible because the last reported sale price of Allscripts common stock for at least 20 consecutive trading days within the 30-trading-day period ending on May 29, 2009 was greater than 130 percent of the conversion price in effect on May 29, 2009. As a result, during the conversion period, holders of the Debentures may convert the Debentures into shares of common stock, subject to the terms of the Indenture. Pursuant to the terms of the Indenture, the Debentures are convertible at the conversion rate of 124.3781 shares per $1,000 principal amount of each Debenture. Allscripts has the right to satisfy the conversion with cash in lieu of shares of common stock in accordance with the terms of the Indenture.

Additionally, Allscripts announced today that, pursuant to the terms of the Indenture, holders of Debentures have the right to require Allscripts to repurchase their Debentures (the "Repurchase Right") for cash in an amount equal to 100 percent of the principal amount of the Debentures ($1,000 per each $1,000 principal amount outstanding) plus accrued and unpaid interest and Liquidated Damages (as defined in the Indenture) to, but excluding, July 15, 2009. The Repurchase Right is subject to the terms and conditions described in the Notice of Right to Require Repurchase sent to Debenture holders and the Indenture. The Repurchase Right will expire at 5:00 p.m., Eastern Daylight Time, on July 15, 2009.


'/>"/>
SOURCE Allscripts
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records
2. Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record
3. JDRF Illinois Names Allscripts CEO Glen Tullman Best of Illinois for His Efforts to Find a Cure for Type 1 Diabetes
4. Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care
5. Cardinal Health to Offer Allscripts Electronic Health Record to Solo and Small Physician Groups
6. Edge Health to Offer Allscripts MyWay(TM) for Mac(R) Electronic Health Record
7. Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year
8. Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008
9. Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk
10. Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk
11. Allscripts Introduces SaaS Solution for Prenatal Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... METTLER TOLEDO has announced an upcoming ... in a GXP Regulated Laboratory ", featuring independent ... will be presented on May 27, 2015 at ... a critical component of pharmaceutical product quality and ... recent years an increasing number of inspections have ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 CCL, a top-ranked, global ... unique program to other leadership development consultancies. “The ... CCL and successful practitioners, expanding our capacity to drive ... said John R. Ryan, CCL President and CEO. , ... CCL Partner Network , it will schedule a one-on-one ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2
... LOS ANGELES, March 5 With the nation focused ... Valley) recently announced Assembly Bill 562 ( ... to businesses and consumers that have fallen victim to ... decreases health care premium costs. It requires insurance companies ...
... YORK, March 5 An article published in the ... , a joint publication of United Spinal Association ( ... Multiple Sclerosis (NARCOMS), reveals the importance of understanding ... it can also lead to a greater understanding and ...
... day for six months were able to increase the flaccid ... erectile function by up to 36%, according to an independent ... International . , Researchers from San Giovanni Battista Hospital at ... treatment could provide a viable alternative to surgery, as the ...
... Sick or injured African-American patients wait about an ... being transferred to an inpatient hospital bed following ... study published in the journal Academic Emergency ... the urgency to find equitable, cost-effective solutions to ...
... Already Breaking down Silos and Benefiting from Paperless ... Waters Corporation (NYSE: WAT ) ... strategic partnership to integrate laboratory software for improved ... Collaborating with existing common customers, Waters(R) and LabVantage(R) ...
... Texas and SAN FRANCISCO, March 5 Preferred ... payment and transaction-processing services for the health care ... ), the world,s largest retail payments network, today ... brand for PHT,s A-Claim(TM) medical payment solution for ...
Cached Medicine News:Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:United Spinal Association Report Reveals the Importance of Studying Multiple Sclerosis in Children: Developing New Insights into MS in Adults 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 4Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 2Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 3
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, Inc. ... Pharmaceuticals, Inc. (NASDAQ: MACK ) with its ... ) jointly announced that Baxter has submitted a ... Agency (EMA) for MM-398 (irinotecan liposome injection), also ... of the pancreas who have been previously treated ...
(Date:5/4/2015)... May 4, 2015  By looking at the ... distinguish between two very different conditions that can ... Henderson , MD, PhD., a Denver ... this study can help the medical ... treatment options, for Post-Traumatic Stress Disorder (PTSD) and ...
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... SAN LEANDRO, Calif., Feb. 14, 2011 Mercator MedSystems, ... treating drug-resistant hypertension, announced today that Neil P. Desai, ... Desai has an extensive background in drug-delivery and global ... Prior to the acquisition of Abraxis Bioscience, Inc. (ABI), ...
... newly approved drug dabigatran is an alternative to warfarin ... atrial fibrillation, according to updated guidelines from the American ... Rhythm Society. (Logo:   http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) ... Circulation: Journal of the American Heart Association, Journal ...
Cached Medicine Technology:Mercator MedSystems Appoints Neil Desai, Ph.D., to Board of Directors 2New Anti-Clotting Drug Added to Recommendations for Treating Irregular Heartbeat 2New Anti-Clotting Drug Added to Recommendations for Treating Irregular Heartbeat 3
Inquire...
Inquire...
One Pair of Knife Raising Blocks to move blade up 1 inch for adpatation of a freezing stage....
CO2 gas object holder and knife freezer for the 8000 Series Sliding Microtome...
Medicine Products: